Theralase Reports Expanded Cancer Drug TechnologyToronto, Ontario -- April 19, 2012 -- Theralase Technologies Inc. (TSX-V:...
Roger Dumoulin-WhitePresident & Chief Executive Officer416-447-8455 ext. 225rwhite@theralase.comKristina HacheyChief Finan...
Upcoming SlideShare
Loading in …5
×

Theralase reports expanded cancer drug technology revised - 19 april 2012

294 views
209 views

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
294
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Theralase reports expanded cancer drug technology revised - 19 april 2012

  1. 1. Theralase Reports Expanded Cancer Drug TechnologyToronto, Ontario -- April 19, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced todaythat it has been issued a new U.S. Patent that expands the scope and capabilities of its cancer-fighting proprietary Photo Dynamic Compound (PDC) technology. The patent providesTheralase with exclusive rights to a new and advanced class of anti-cancer and anti-bacterialcompounds until 2031.Theralase continues to expand its intellectual property holdings of cancer-fighting drugcompounds employed in conjunction with its proprietary therapeutic laser device capabilities.The newly issued U.S. Patent expands the Company’s capability to jointly employ its proprietaryPDC and laser technologies in the destruction of a diverse variety of common cancers, bacteriaand viruses. The new PDC patent identifies a special class of proprietary Photo DynamicCompounds that can be employed in the destruction of bulk tumours.Theralase recently reported that the growth of subcutaneous (under the skin) colon cancertumours in mouse subjects, which were simultaneously treated with the Theralase anti-cancerPDC technologies have continued to thrive cancer-free for more than 55 days post-treatmentand without any side effects.Based on the Company’s recent successes in the research and development of its portfolio ofpatented PDCs, there is increased confidence that applications can be made to the regulatorybodies for human trials in the relatively near future.About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing. Theralase is currently developing patented PhotoDynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when lightactivated by Theralase’s proprietary and patented laser technology.For further information please visit www.theralase.com, regulatory filings may be viewed by visitingwww.sedar.com.This press release contains forward-looking statements which reflect the Companys current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims anyobligation to update these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More Information:
  2. 2. Roger Dumoulin-WhitePresident & Chief Executive Officer416-447-8455 ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-447-8455 ext. 224khachey@theralase.comArkady MandelChief Scientific Officer416-447-8455 ext. 242amandel@theralase.comGreg BewshDirector of Investor Relations416-447-8455 ext. 262gbewsh@theralase.com

×